HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: M600375-MCP200v1 6/6/963    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morphew, R. M. Articles by Brophy, P. M. Search for Related Content PubMed PubMed Citation Articles by Morphew, R. M. Articles by Brophy, P. M. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 6:963-972, 2007.
© 2007 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Comparative Proteomics of Excretory-Secretory Proteins Released by the Liver Fluke Fasciola hepatica in Sheep Host Bile and during in Vitro Culture ex Host^*,S

Russell M. Morphew^,, Hazel A. Wright, E. James LaCourse^¶, Debra J. Woods^|| and Peter M. Brophy

From the Institute of Biological Sciences, University of Wales, Aberystwyth, Wales SY23 3DA, United Kingdom, ^|| Pfizer Animal Health, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom, and ^¶ School of Biological Sciences, Liverpool University, Crown Street, Liverpool L69 7ZB, United Kingdom

Livestock infection by the parasitic fluke Fasciola hepatica causes major economic losses worldwide. The excretory-secretory (ES) products produced by F. hepatica are key players in understanding the host-parasite interaction and offer targets for chemo- and immunotherapy. For the first time, subproteomics has been used to compare ES products produced by adult F. hepatica in vivo, within ovine host bile, with classical ex host in vitro ES methods. Only cathepsin L proteases from F. hepatica were identified in our ovine host bile preparations. Several host proteins were also identified including albumin and enolase with host trypsin inhibitor complex identified as a potential biomarker for F. hepatica infection. Time course in vitro analysis confirmed cathepsin L proteases as the major constituents of the in vitro ES proteome. In addition, detoxification proteins (glutathione transferase and fatty acid-binding protein), actin, and the glycolytic enzymes enolase and glyceraldehyde-3-phosphate dehydrogenase were all identified in vitro. Western blotting of in vitro and in vivo ES proteins showed only cathepsin L proteases were recognized by serum pooled from F. hepatica-infected animals. Other liver fluke proteins released during in vitro culture may be released into the host bile environment via natural shedding of the adult fluke tegument. These proteins may not have been detected during our in vivo analysis because of an increased bile turnover rate and may not be recognized by pooled liver fluke infection sera as they are only produced in adults. This study highlights the difficulties identifying authentic ES proteins ex host, and further confirms the potential of the cathepsin L proteases as therapy candidates.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. W. Robinson, J. F. Tort, J. Lowther, S. M. Donnelly, E. Wong, W. Xu, C. M. Stack, M. Padula, B. Herbert, and J. P. Dalton Proteomics and Phylogenetic Analysis of the Cathepsin L Protease Family of the Helminth Pathogen Fasciola hepatica: Expansion of a Repertoire of Virulence-associated Factors Mol. Cell. Proteomics, June 1, 2008; 7(6): 1111 - 1123. [Abstract] [Full Text] [PDF]

				A. Marcilla, J. E. De la Rubia, J. Sotillo, D. Bernal, C. Carmona, Z. Villavicencio, D. Acosta, J. Tort, F. J. Bornay, J. G. Esteban, et al. Leucine Aminopeptidase Is an Immunodominant Antigen of Fasciola hepatica Excretory and Secretory Products in Human Infections Clin. Vaccine Immunol., January 1, 2008; 15(1): 95 - 100. [Abstract] [Full Text] [PDF]